使用新型单克隆抗体SM-3对卵巢肿瘤进行放射免疫闪烁成像。

Radioimmunoscintigraphy of ovarian tumors using a new monoclonal antibody, SM-3.

作者信息

Jobling T W, Granowska M, Britton K E, Lowe D G, Mather S J, Burchell J, Naeem M, Shepherd J H

机构信息

Department of Gynaecological Oncology, Nuclear Medicine, and Histopathology, St. Bartholomew's Hospital, London, England.

出版信息

Gynecol Oncol. 1990 Sep;38(3):468-72. doi: 10.1016/0090-8258(90)90093-z.

DOI:10.1016/0090-8258(90)90093-z

PMID:2227563

Abstract

Radioimmunoscintigraphy with SM-3 monoclonal antibody produces results similar to those obtained with 123I-labeled HMFG-2. The tumor specificity of SM-3 in vitro is not as marked as that in vivo. SM-3 is, however, much easier to produce in tissue culture and, with the availability of 99mTc labelling, has allowed radioimmunoscintigraphy to be done as an outpatient procedure. This technique has important implications for the continuing management of patients with ovarian cancer.

摘要

使用SM-3单克隆抗体的放射免疫闪烁成像产生的结果与使用123I标记的HMFG-2所获得的结果相似。SM-3在体外的肿瘤特异性不如在体内明显。然而，SM-3在组织培养中更容易产生，并且由于99mTc标记的可用性，使得放射免疫闪烁成像可以作为门诊程序进行。这项技术对卵巢癌患者的持续管理具有重要意义。